A Multicenter, Open-Label Study of LYC-55716 in Combination With Pembrolizumab in Adult Subjects With Metastatic Non-Small Cell Lung Cancer
Phase of Trial: Phase I
Latest Information Update: 23 Oct 2018
At a glance
- Drugs LYC 55716 (Primary) ; Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Proof of concept
- Sponsors Lycera
- 05 Jun 2018 Trial design presented at 54th Annual Meeting of the American Society of Clinical Oncology.
- 17 Apr 2018 According to a Lycera media release, company anticipate to report top-line efficacy findings from this study by or before mid-2019.
- 08 Jan 2018 New trial record